Literature DB >> 2171330

Pseudohypophosphatasia: aberrant localization and substrate specificity of alkaline phosphatase in cultured skin fibroblasts.

K N Fedde1, D E Cole, M P Whyte.   

Abstract

We explored the biochemical basis for the disorder pseudohypophosphatasia (PsHYPT) in one patient by examining the substrate specificity and localization of alkaline phosphatase (ALP) in cultured dermal fibroblasts. Despite substantial ALP activity, in cell homogenates, toward the artificial substrate 4-methyl-umbelliferyl phosphate (4-MUP), there was a marked deficiency in ALP activity toward the natural substrates pyridoxal 5'-phosphate (PLP) and phosphoethanolamine (PEA), indicating altered substrate specificity. Furthermore, although 4-MUP phosphatase (4-MUP-P'tase) activity was predominantly localized as an ecto-enzyme, the small amount of PLP phosphatase (PLP-P'tase) activity was intracellular. This differential localization was apparent in intact cells, since (1) brief acidification of the medium at 4 degrees C inactivated a majority of the 4-MUP-P'tase activity but only 15% of the PLP-P'tase activity (in contrast to greater than 85% inactivation of both in homogenates), (2) greater than 70% of the 4-MUP-P'tase activity but only 30% of the PLP-P'tase activity was released by phosphatidylinositol-specific phospholipase C (PI-PLC) digestion, and (3) degradation of extracellular PLP was less than 35% of that of disrupted cells. Both 4-MUP- and PLP-P'tase activities were predominantly in a lipid-anchored form that could be converted to a soluble, lipid-free form by PI-PLC digestion. Our findings suggest that the clinical and biochemical presentation of this PSHPT patient results from the production of two aberrant ALP species. One form of ALP has appropriate ectoorientation but is preferentially deficient in activity toward natural substrates; the other ALP species has appropriate substrate specificity but is sequestered from substrates by its intracellular location.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2171330      PMCID: PMC1683693     

Source DB:  PubMed          Journal:  Am J Hum Genet        ISSN: 0002-9297            Impact factor:   11.025


  13 in total

1.  Alkaline phosphatase is an ectoenzyme that acts on micromolar concentrations of natural substrates at physiologic pH in human osteosarcoma (SAOS-2) cells.

Authors:  K N Fedde; C C Lane; M P Whyte
Journal:  Arch Biochem Biophys       Date:  1988-08-01       Impact factor: 4.013

2.  Pseudohypophosphatasia.

Authors:  C R Scriver; D Cameron
Journal:  N Engl J Med       Date:  1969-09-11       Impact factor: 91.245

3.  Increased serum pyridoxal-5'-phosphate in pseudohypophosphatasia.

Authors:  D E Cole; S R Salisbury; R A Stinson; S P Coburn; L M Ryan; M P Whyte
Journal:  N Engl J Med       Date:  1986-04-10       Impact factor: 91.245

4.  Alkaline phosphatase (tissue-nonspecific isoenzyme) is a phosphoethanolamine and pyridoxal-5'-phosphate ectophosphatase: normal and hypophosphatasia fibroblast study.

Authors:  K N Fedde; M P Whyte
Journal:  Am J Hum Genet       Date:  1990-11       Impact factor: 11.025

5.  Adult hypophosphatasia: generalized deficiency of alkaline phosphatase activity demonstrated with cultured skin fibroblasts.

Authors:  M P Whyte; L A Vrabel; T D Schwartz
Journal:  Trans Assoc Am Physicians       Date:  1982

6.  Hypophosphatasia: biochemical screening of a Dutch kindred and evidence that urinary excretion of inorganic pyrophosphate is a marker for the disease.

Authors:  J D Macfarlane; B J Poorthuis; J J van de Kamp; R G Russell; A M Caswell
Journal:  Clin Chem       Date:  1988-09       Impact factor: 8.327

7.  Identification of a variant of mucolipidosis III (pseudo-Hurler polydystrophy): a catalytically active N-acetylglucosaminylphosphotransferase that fails to phosphorylate lysosomal enzymes.

Authors:  A P Varki; M L Reitman; S Kornfeld
Journal:  Proc Natl Acad Sci U S A       Date:  1981-12       Impact factor: 11.205

8.  A missense mutation in the human liver/bone/kidney alkaline phosphatase gene causing a lethal form of hypophosphatasia.

Authors:  M J Weiss; D E Cole; K Ray; M P Whyte; M A Lafferty; R A Mulivor; H Harris
Journal:  Proc Natl Acad Sci U S A       Date:  1988-10       Impact factor: 11.205

9.  Tay-Sachs disease with hexosaminidase A: characterization of the defective enzyme in two patients.

Authors:  J Bayleran; P Hechtman; E Kolodny; M Kaback
Journal:  Am J Hum Genet       Date:  1987-10       Impact factor: 11.025

10.  Markedly increased circulating pyridoxal-5'-phosphate levels in hypophosphatasia. Alkaline phosphatase acts in vitamin B6 metabolism.

Authors:  M P Whyte; J D Mahuren; L A Vrabel; S P Coburn
Journal:  J Clin Invest       Date:  1985-08       Impact factor: 14.808

View more
  1 in total

1.  Perspective on Dentoalveolar Manifestations Resulting From PHOSPHO1 Loss-of-Function: A Form of Pseudohypophosphatasia?

Authors:  Fatma F Mohamed; Michael B Chavez; Flavia Amadeu de Oliveira; Sonoko Narisawa; Colin Farquharson; José Luis Millán; Brian L Foster
Journal:  Front Dent Med       Date:  2022-02-03
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.